Allison August1, Gregory M Glenn2, Eloi Kpamegan3, Somia P Hickman4, Dewal Jani5, Hanxin Lu6, D Nigel Thomas7, Judy Wen8, Pedro A Piedra9, Louis F Fries10. 1. Novavax, Inc., 20 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: allison.august11@gmail.com. 2. Novavax, Inc., 20 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: gglenn@novavax.com. 3. Novavax, Inc., 20 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: kepg47@gmail.com. 4. Novavax, Inc., 20 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: shickman@novavax.com. 5. Novavax, Inc., 20 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: djani@novavax.com. 6. Novavax, Inc., 20 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: hlu@novavax.com. 7. Novavax, Inc., 20 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: nthomas@novavax.com. 8. Novavax, Inc., 20 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: jwen@novavax.com. 9. Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA. Electronic address: ppiedra@bcm.edu. 10. Novavax, Inc., 20 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: lfries@novavax.com.
Abstract
OBJECTIVE: Respiratory syncytial virus (RSV) causes significant morbidity and mortality in infants. We are developing an RSV fusion (F) protein nanoparticle vaccine for immunization of third trimester pregnant women to passively protect infants through transfer of RSV-specific maternal antibodies. The present trial was performed to assess the immunogenicity and safety of several formulations of RSV F vaccine in 1-dose or 2-dose schedules. METHODS:Placebo, or vaccine with 60μg or 120μg RSV F protein and 0.2, 0.4, or 0.8mg aluminum, were administered intramuscularly on Days 0 and 28 to healthy women 18-35years old. Immunogenicity was assessed from Days 0 through 91 based on anti-F IgG and palivizumab-competitive antibody (PCA) by ELISA, and RSV A and B neutralizing antibodies by microneutralization (MN) assay. Solicited adverse events were collected through Day 7 and unsolicited adverse events through Day 91. RESULTS: All formulations were well-tolerated, with no treatment-related serious adverse events. Anti-F IgG and PCA responses were correlated and increased after both doses, while MN increased significantly only after the first dose, then plateaued. The timeliest and most robust antibody responses followed one dose of 120μg RSV F protein and 0.4mg aluminum, but persistence through 91days was modestly (∼25%) superior following two doses of 60μg RSV F protein and 0.8mg aluminum. Western blot analysis showed RSV infections in active vaccinees were reduced by 52% overall (p=0.009 overall) over the Day 0 through 90 period. CONCLUSIONS: RSV F nanoparticle vaccine formulations were well tolerated and immunogenic. The optimal combination of convenience and rapid response for immunization in the third trimester occurred with 120μg RSV F and 0.4mg aluminum, which achieved peak immune responses in 14days and sufficient persistence through 91days to allow for passive transfer of IgG antibodies to the fetus. NCT01960686.
RCT Entities:
OBJECTIVE:Respiratory syncytial virus (RSV) causes significant morbidity and mortality in infants. We are developing an RSV fusion (F) protein nanoparticle vaccine for immunization of third trimester pregnant women to passively protect infants through transfer of RSV-specific maternal antibodies. The present trial was performed to assess the immunogenicity and safety of several formulations of RSV F vaccine in 1-dose or 2-dose schedules. METHODS: Placebo, or vaccine with 60μg or 120μg RSV F protein and 0.2, 0.4, or 0.8mg aluminum, were administered intramuscularly on Days 0 and 28 to healthy women 18-35years old. Immunogenicity was assessed from Days 0 through 91 based on anti-F IgG and palivizumab-competitive antibody (PCA) by ELISA, and RSV A and B neutralizing antibodies by microneutralization (MN) assay. Solicited adverse events were collected through Day 7 and unsolicited adverse events through Day 91. RESULTS: All formulations were well-tolerated, with no treatment-related serious adverse events. Anti-F IgG and PCA responses were correlated and increased after both doses, while MN increased significantly only after the first dose, then plateaued. The timeliest and most robust antibody responses followed one dose of 120μg RSV F protein and 0.4mg aluminum, but persistence through 91days was modestly (∼25%) superior following two doses of 60μg RSV F protein and 0.8mg aluminum. Western blot analysis showed RSV infections in active vaccinees were reduced by 52% overall (p=0.009 overall) over the Day 0 through 90 period. CONCLUSIONS:RSV F nanoparticle vaccine formulations were well tolerated and immunogenic. The optimal combination of convenience and rapid response for immunization in the third trimester occurred with 120μg RSV F and 0.4mg aluminum, which achieved peak immune responses in 14days and sufficient persistence through 91days to allow for passive transfer of IgG antibodies to the fetus. NCT01960686.
Authors: Edward E Walsh; Lu Wang; Ann R Falsey; Xing Qiu; Anthony Corbett; Jeanne Holden-Wiltse; Thomas J Mariani; David J Topham; Mary T Caserta Journal: J Infect Dis Date: 2018-06-20 Impact factor: 5.226
Authors: Jorge C G Blanco; Marina S Boukhvalova; Trudy G Morrison; Stefanie N Vogel Journal: Hum Vaccin Immunother Date: 2018-06-19 Impact factor: 3.452
Authors: Anne M Hause; Lakshmi Panagiotakopoulos; Eric S Weintraub; Lina S Sy; Sungching C Glenn; Hung-Fu Tseng; Michael M McNeil Journal: Clin Infect Dis Date: 2021-01-23 Impact factor: 9.079
Authors: Xunyan Ye; Obinna P Iwuchukwu; Vasanthi Avadhanula; Letisha O Aideyan; Trevor J McBride; David M Henke; Kirtida D Patel; Felipe-Andres Piedra; Laura S Angelo; Dimpy P Shah; Roy F Chemaly; Pedro A Piedra Journal: Viruses Date: 2021-05-26 Impact factor: 5.048